The pharmaceutical firm reported third-quarter earnings and gross sales that beat analysts’ expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and rising demand for blockbuster anti-inflammatory drug Dupixent.
in Business
Sanofi Earnings Boosted by Early Vaccine Sales
